Last edition
News about "BELLUS Health Inc,"
BELLUS Health Inc.is pleased to announce that it has closed the transaction announced on March 23, 2020 in accordance with the asset purchase and sale agreement entered into with adMare BioInnovations’ NEOMED Institute
BELLUS Health Inc, | 27/03/2020 | By Darshana | 241
BELLUS Health Inc, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has entered into an asset purchase and sale agreement to acquire all of the remaining BLU-5937 and related P2X3 antagonists intellectual property assets.
BELLUS Health Inc, | 24/03/2020 | By Darshana | 317
BELLUS Health Inc, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has completed patient enrollment for the RELIEF trial, its dose-escalation, placebo-controlled Phase 2 trial of BLU-5937 in patients
BELLUS Health Inc, | 21/03/2020 | By Darshana | 275
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy